Nabriva Therapeutics AG   Report issue

Contributed to NME For profit Phase 2 Phase 3
Founded: Vienna Austria (2001)

Organization Overview

First Clinical Trial
2010
NCT01119105
First Marketed Drug
2019
lefamulin (Xenleta)
First NDA Approval
2019
lefamulin (Xenleta)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NABRIVA | Nabriva Therapeutics | Nabriva Therapeutics AG